|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
IRCT |
|
Last refreshed on:
|
26 August 2019 |
|
Main ID: |
IRCT20190430043438N1 |
|
Date of registration:
|
2019-06-17 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
The effect of Biotin and Dexpanthenol on androgenetic alopecia
|
|
Scientific title:
|
The effect of Biotin and Dexpanthenol on hair loss in patients with androgenetic alopecia |
|
Date of first enrolment:
|
2018-12-06 |
|
Target sample size:
|
90 |
|
Recruitment status: |
Complete |
|
URL:
|
http://en.irct.ir/trial/39291 |
|
Study type:
|
interventional |
|
Study design:
|
Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive.
|
|
Phase:
|
2-3
|
|
|
Countries of recruitment
|
|
Iran (Islamic Republic of)
| | | | | | | |
|
Contacts
|
|
Name:
|
Yadollah Azarmi
|
|
Address:
|
Tabriz University of Medical Sciences, Daneshgah street, Tabriz
5166614766
Tabriz
Iran (Islamic Republic of) |
|
Telephone:
|
+98 41 3334 6074 |
|
Email:
|
info@pharmfac.tbzmed.ac.ir |
|
Affiliation:
|
Tabriz University of Medical Sciences |
|
|
Name:
|
Sanaz Ghasempour
|
|
Address:
|
Tabriz University of Medical Sciences, Daneshgah street, Tabriz
5166614766
Tabriz
Iran (Islamic Republic of) |
|
Telephone:
|
+98 41 3335 5921 |
|
Email:
|
ghasempour_sanaz@yahoo.com |
|
Affiliation:
|
Tabriz University of Medical Sciences |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Men with androgenetic hair loss type 1 to 4
Exclusion criteria: Having varicocele
Willing to get pregnant
Age minimum:
18 years
Age maximum:
50 years
Gender:
Male
|
|
Health Condition(s) or Problem(s) studied
|
Androgenic alopecia.
Other androgenic alopecia
|
|
L64.8
|
|
Intervention(s)
|
|
Intervention 1: Control group: Minoxidil solution 5%, produced by Pak darou inc, 20 drops, twice a day, for 3 months and finasteride 1 mg tablet, produced by Shafa inc, 1 tablet daily for 3 months. Intervention 2: Intervention group 1: Minoxidil solution 5%, produced by Pak darou inc, 20 drops twice a day for 3 months and Finasteride tablet 1 mg, produced by Shafa inc, 1 tablet daily for 3 months and Biotin IM injections 5 mg / ml, produced by Oxin darou vesht, every 5 days for 3 months. Intervention 3: Intervention group 2: Minoxidil solution 5% of the Pak darou inc, twice daily 20 drops for 3 months and Finasteride tablet 1 mg of Shafa inc, 1tablet daily for 3 months and biotin ampoule 5 mg / ml Oxin darou vesht every 5 days for 3 months (IM) And dexpantol ampoule 500 mg / 2 ml each. Oxin darou vesht every 5 days for 3 month (IM).
|
|
Primary Outcome(s)
|
|
Score of hair loss. Timepoint: Measuring hair loss at the beginning of the study (before the intervention) and 30, 60 and 90 days after the start of the medication. Method of measurement: Monthly scoring for hair loss of 10 based on patient's claim.
|
|
The hair thickness. Timepoint: Measuring the thickness of the hair at the beginning of the study (before the intervention) and 30, 60 and 90 days after the start of the medication. Method of measurement: Trichoscope.
|
|
The number of hair in a circle 2.54 cm in diameter. Timepoint: Counting the number of hair at the beginning of the study (before the intervention) and 30, 60 and 90 days after starting the medication. Method of measurement: Macrophotography technique.
|
|
Source(s) of Monetary Support
|
|
Oxin darou Vesht
|
|
Tabriz University of Medical Sciences
|
|
Ethics review
|
Status: Approved
Approval date:
Contact:
Ethics committee of Tabriz University of Medical Sciences
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|